Información del artículo
The present article is an update of the literature on lower respiratory tract infections in critical patients.
A multidisciplinary group of Spanish physicians with expertise in the field selected what they considered to be the most important papers published during 2004 and 2005. Each article was analyzed and discussed by one of the members of the panel.
A critical review of all these contributions constitutes the body of this paper.
After a review of the state of the art, papers selected in the field of new guidelines, risk factors, new diagnostic methods, antimicrobial therapy, and prevention are discussed.
Key words:
Pneumonia
Ventilator-associated pneumonia
Community-acquired pneumonia
Guidelines
Quantitative diagnostic methods
CPIS
Therapy
El artículo presente recoge una actualización de la bibliografía médica relativa a las infecciones del tracto respiratorio inferior en los pacientes en situación clínica crítica. Un grupo multidisciplinario de clínicos españoles con experiencia en este área seleccionó los que consideró los artículos más importantes sobre este campo publicados en 2004 y 2005. Cada artículo fue analizado y discutido por uno de los miembros del grupo.
El artículo presente recoge una revisión crítica de todas estas contribuciones. Tras una revisión de la situación actual, se comentaron los artículos seleccionados relativos a las nuevas directrices, los factores de riesgo, los nuevos métodos diagnósticos, el tratamiento antimicrobiano y la prevención.
Palabras clave:
Neumonía
Neumonía asociada a respirador
Neumonía extrahospitalaria
Directrices
Métodos diagnósticos cuantitativos
CPIS
Tratamiento
El Texto completo está disponible en PDF
References
[1.]
D.E. Craven, R. Palladino, D.P. McQuillen.
Healthcare-associated pneumonia in adults: management principles to improve outcomes.
Infect Dis Clin North Am, 18 (2004), pp. 939-962
[2.]
C.E. Luyt, J. Chastre, J.Y. Fagon.
Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia.
Intensive Care Med, 30 (2004), pp. 844-852
[3.]
H. Mentec, L. May-Michelangeli, A. Rabbat, E. Varon, F. Le Turdu, G. Bleichner.
Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia. A multicentre prospective study.
Intensive Care Med, 30 (2004), pp. 1319-1326
[4.]
A.F. Shorr, M.S. Duh, K.M. Kelly, M.H. Kollef.
Red blood cell transfusion and ventilator-associated pneumonia: A potential link?.
Crit Care Med, 32 (2004), pp. 666-674
[5.]
L. Lorente, M. Lecuona, M.M. Martín, C. Garcia, M.L. Mora, A. Sierra.
Ventilator-associated pneumonia using a closed versus an open tracheal suction system.
Crit Care Med, 33 (2005), pp. 115-119
[6.]
M.H. Kollef, K.E. Kollef.
Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results.
Chest, 128 (2005), pp. 2706-2713
[7.]
M. Ioanas, M. Ferrer, M. Cavalcanti, R. Ferrer, S. Ewig, X. Filella, et al.
Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia.
Crit Care Med, 32 (2004), pp. 938-945
[8.]
J.R. Zahar, C. Clec’h, M. Tafflet, M. Garrouste-Orgeas, S. Jamali, B. Mourvillier, et al.
Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?.
Clin Infect Dis, 41 (2005), pp. 1224-1231
[9.]
M.H. Kollef, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, R.G. Wunderink.
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
Intensive Care Med, 30 (2004), pp. 388-394
[10.]
G.W. Soo Hoo, Y.E. Wen, T.V. Nguyen, M.B. Goetz.
Impact of clinical guidelines in the management of severe hospital-acquired pneumonia.
Chest, 128 (2005), pp. 2778-2787
[11.]
M. Bodi, A. Rodriguez, J. Sole-Violan, M.C. Gilavert, J. Garnacho, J. Blanquer, et al.
Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival.
Clin Infect Dis, 41 (2005), pp. 1709-1716
[12.]
R. Menendez, A. Torres, F. Rodriguez de Castro, R. Zalacain, J. Aspa, J.J. Martin Villasclaras, et al.
Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.
Clin Infect Dis, 39 (2004), pp. 1783-1790
[13.]
M. Confalonieri, R. Urbino, A. Potena, M. Piattella, P. Parigi, G. Puccio, et al.
Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.
Am J Respir Crit Care Med, 171 (2005), pp. 242-248
[14.]
H.L. Corwin, A. Gettinger, R.G. Pearl, M.P. Fink, M.M. Levy, E. Abraham, et al.
The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.
Crit Care Med, 32 (2004), pp. 39-52
[15.]
S.K. Pingleton, J.Y. Fagon, K.V. Leeper Jr.
Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques.
Chest, 102 (1992), pp. 553S-556S
[16.]
R.W. Taylor, L. Manganaro, J. O’Brien, S.J. Trottier, N. Parkar, C. Veremakis.
Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient.
Crit Care Med, 30 (2002), pp. 2249-2254
[17.]
J.A. Claridge, R.G. Sawyer, A.M. Schulman, E.C. McLemore, J.S. Young.
Blood transfusions correlate with infections in trauma patients in a dose-dependent manner.
Am Surg, 68 (2002), pp. 566-572
[18.]
M.A. Croce, T.C. Fabian, L. Waddle-Smith, R.A. Maxwell.
Identification of early predictors for post-traumatic pneumonia.
Am Surg, 67 (2001), pp. 105-110
[19.]
S.G. Weber, H.S. Gold, D.C. Hooper, A.W. Karchmer, Y. Carmeli.
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients.
Emerg Infect Dis, 9 (2003), pp. 1415-1422
[20.]
J. Rello, A. Torres, M. Ricart, J. Valles, J. Gonzalez, A. Artigas, et al.
Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes.
Am J Respir Crit Care Med, 150 (1994), pp. 1545-1549
[21.]
A.F. Shorr, M.J. Kunkel, M. Kollef.
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
J Antimicrob Chemother, 56 (2005), pp. 923-929
[22.]
S. Osmon, S. Ward, V.J. Fraser, M.H. Kollef.
Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.
Chest, 125 (2004), pp. 607-616
[23.]
E.H. Ibrahim, S. Ward, G. Sherman, R. Schaiff, V.J. Fraser, M.H. Kollef.
Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.
Crit Care Med, 29 (2001), pp. 1109-1115
[24.]
L.A. Mandell, T.J. Marrie, R.F. Grossman, A.W. Chow, R.H. Hyland.
Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.
Can Respir J, 7 (2000), pp. 371-382
[25.]
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
Thorax, 56 (2001), pp. IV1-IV64
[26.]
L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File Jr, D.M. Musher, C. Whitney.
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis, 37 (2003), pp. 1405-1433
[27.]
L. Alvarez-Rocha, J.L. Alos, J. Blanquer, F. Alvarez-Lerma, J. Garau, A. Guerrero, et al.
Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital.
Medicina Intensiva, 29 (2005), pp. 21-62
[28.]
M.S. Niederman, L.A. Mandell, A. Anzueto, J.B. Bass, W.A. Broughton, G.D. Campbell, et al.
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[29.]
M.S. Niederman, J.B. Bass Jr., G.D. Campbell, A.M. Fein, R.F. Grossman, L.A. Mandell, et al.
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association.
Am Rev Respir Dis, 148 (1993), pp. 1418-1426
[30.]
A. Capelastegui, P.P. España, J.M. Quintana, I. Gorordo, M. Ortega, I. Idoiaga, et al.
Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.
Clin Infect Dis, 39 (2004), pp. 955-963
[31.]
N.C. Dean, M.P. Silver, K.A. Bateman, B. James, C.J. Hadlock, D. Hale.
Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia.
Am J Med, 110 (2001), pp. 451-457
[32.]
M.J. Fine, R.A. Stone, J.R. Lave, L.J. Hough, D.S. Obrosky, M.K. Mor, et al.
Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial.
Am J Med, 115 (2003), pp. 343-351
[33.]
P.P. Gleason, W.N. Kapoor, R.A. Stone, J.R. Lave, D.S. Obrosky, R. Schulz, et al.
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.
JAMA, 278 (1997), pp. 32-39
[34.]
P.P. Gleason, T.P. Meehan, J.M. Fine, D.H. Galusha, M.J. Fine.
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
Arch Intern Med, 159 (1999), pp. 2562-2572
[35.]
T.K. Marras, C.K. Chan.
Use of guidelines in treating community-acquired pneumonia.
Chest, 113 (1998), pp. 1689-1694
[36.]
T.J. Marrie, C.Y. Lau, S.L. Wheeler, C.J. Wong, M.K. Vandervoort, B.G. Feagan.
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
JAMA, 283 (2000), pp. 749-755
[37.]
R. Menéndez, D. Ferrando, J.M. Vallés, J. Vallterra.
Influence of deviation from guidelines on the outcome of community-acquired pneumonia.
Chest, 122 (2002), pp. 612-617
[38.]
E.M. Mortensen, M. Restrepo, A. Anzueto, J. Pugh.
Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia.
Am J Med, 117 (2004), pp. 726-731
[39.]
S.R. Weingarten, M.S. Riedinger, P. Hobson, M.S. Noah, B. Johnson, G. Giugliano, et al.
Evaluation of a pneumonia practice guideline in an interventional trial.
Am J Respir Crit Care Med, 153 (1996), pp. 1110-1115
[40.]
T.J. Marrie, K.C. Carriere, Y. Jin, D.H. Johnson.
Mortality during hospitalization for pneumonia in Alberta, Canada, is associated with physician volume.
Eur Respir J, 22 (2003), pp. 148-155
[41.]
R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, J. Cohen, et al.
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Crit Care Med, 32 (2004), pp. 858-873
[42.]
E.M. Mortensen, C.M. Coley, D.E. Singer, T.J. Marrie, D.S. Obrosky, W.N. Kapoor, et al.
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study.
Arch Intern Med, 162 (2002), pp. 1059-1064
[43.]
S. Ewig, A. Torres, M. Woodhead.
Assessment of pneumonia severity: a European perspective.
Eur Respir J, 27 (2006), pp. 6-8
[44.]
S. Ewig, M. Ruiz, J. Mensa, M.A. Marcos, J.A. Martínez, F. Arancibia, et al.
Severe community-acquired pneumonia. Assessment of severity criteria.
Am J Respir Crit Care Med, 158 (1998), pp. 1102-1108
Copyright © 2007. Elsevier España S.L.. All rights reserved
